<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113395</url>
  </required_header>
  <id_info>
    <org_study_id>ALR_2019_14</org_study_id>
    <nct_id>NCT04113395</nct_id>
  </id_info>
  <brief_title>Concordance and Accuracy of MRI in the Detection of Meningiomas: Optimizing Sequences With Low Doses of Gadolinium</brief_title>
  <acronym>CAMOMILLE</acronym>
  <official_title>Concordance and Accuracy of Magnetic Resonance Imaging in the Detection of Meningiomas: Optimizing Sequences With Low Doses of Gadolinium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Meningioma, an extra-axial brain tumor developed at the expense of meninges, accounts for 35%&#xD;
      of central nervous system tumors, and its incidence is estimated at 3% in large autopsy&#xD;
      series.&#xD;
&#xD;
      The current gold standard for screening and monitoring cerebral meningiomas is MRI with&#xD;
      injection of gadoline-contrast product. However, the use of some of these products is&#xD;
      problematic, due to gadolinium deposits observed in patients who have had several injections&#xD;
      during their lifetime, especially in patients followed for multiple sclerosis.&#xD;
&#xD;
      Recently, the French National Agency for the Safety of Medicines and Health Products (ANSM)&#xD;
      issued recommendations concerning the screening of meningiomas in patients at risk,&#xD;
      particularly in people treated with cyproterone acetate. It is a synthetic progestogen&#xD;
      steroid with anti-androgenic properties. It is used to treat hyperandrogenic syndromes in&#xD;
      women or in the palliative treatment of prostate cancer in men. Its long-term use seems to be&#xD;
      associated with a significant over-risk of developing meningiomas, brain tumours affecting&#xD;
      meninges. This increased risk is multiplied by 7 in women exposed to high doses of&#xD;
      cyproterone acetate, and by 20 over a cumulative dose of 60 grams, or about 5 years of&#xD;
      treatment at 50 mg/day or 10 years at 25 mg/day. The ANSM recommends that a cerebral MRI be&#xD;
      performed at the beginning of treatment for all patients, as well as a control MRI renewed at&#xD;
      5 years and then every 2 years if the MRI at 5 years is normal. These recommendations will&#xD;
      lead to a large number of MRIs involving an injection of contrast agent in this population,&#xD;
      with potential immediate or delayed serious adverse effects.&#xD;
&#xD;
      New techniques, such as Arterial Spin Labelling (ASL), or black blood sequences optimized for&#xD;
      contrast detection, have been developed. These could detect meningeal anomalies and more&#xD;
      particularly meningiomas without contrast injection, or with a significantly lower dose of&#xD;
      contrast agent.&#xD;
&#xD;
      These techniques have not been specifically studied for screening or monitoring meningeal&#xD;
      lesions, but it seems relevant and important to be able to validate protocols that reduce&#xD;
      gadolinium doses given the high number of screening and follow-up MRIs in the general&#xD;
      population.&#xD;
&#xD;
      Patients presenting for brain MRI screening or meningioma follow-up will have the usual MRI&#xD;
      sequences for their management, and the sequences performed at 1/6th of the standard dose of&#xD;
      Gadolinium that are added for research. These new sequences will add approximately 6 minutes&#xD;
      of additional examination time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2019</start_date>
  <completion_date type="Anticipated">December 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the diagnostic concordance in terms of meningioma detection between the 3T MRI sequences with a Gadolinium injection reduced to 1/6th and the full dose sequences (Gold Standard).</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Meningioma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sequences T1 FE</intervention_name>
    <description>T1 TSE and T1 TFE sequences with a duration of 6 minutes are added to the imaging protocol.</description>
    <other_name>T1 TFE sequences</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to the radiology department of the Adolphe de Rothschild Foundation for&#xD;
        an MRI, as part of a screening or monitoring of meningioma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years of age&#xD;
&#xD;
          -  Patient performing MRI as part of a screening or follow-up of known meningioma&#xD;
&#xD;
          -  Express consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication for MRI (electrical device, metallic foreign body, claustrophobia)&#xD;
&#xD;
          -  Known hypersensitivity to the contrast medium (Gadolinium)&#xD;
&#xD;
          -  Known renal failure: glomerular filtration rate &lt;30mL/min&#xD;
&#xD;
          -  Patient benefiting from a legal protection measure&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amelie YAVCHITZ, PhD</last_name>
    <phone>0148036454</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Augustin Lecler</last_name>
    <phone>0418036401</phone>
    <email>alecler@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrice MENEGON</last_name>
      <email>patrice.menegon@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice MENEGON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvie Grand</last_name>
      <email>SGrand@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvie Grand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aymeric ROUCHAUD</last_name>
      <email>aymeric.rouchaud@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aymeric ROUCHAUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Cotton</last_name>
      <email>francois.cotton@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>François Cotton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus GARCIA</last_name>
      <email>jesus.aguilargarcia@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Jesus GARCIA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation ophtalmique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augustin Lecler, MD</last_name>
      <email>alecler@fo-rothschild.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Béatrice CARSIN-NICOL</last_name>
      <email>Beatrice.CARSIN.NICOL@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Béatrice CARSIN-NICOL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel GERARDIN</last_name>
      <email>Emmanuel.Gerardin@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel GERARDIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seyyid BALOGLU</last_name>
      <email>seyyid.baloglu@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Seyyid BALOGLU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Philippe COTTIER</last_name>
      <email>jean-philippe.cottier@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Philippe COTTIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

